Recurrence of COVID symptoms on 07-May-2022  after completing Paxlovid with negative rapid antigen test turning positive again.; This spontaneous case was reported by an other health care professional and describes the occurrence of COVID-19 (Recurrence of COVID symptoms on 07-May-2022  after completing Paxlovid with negative rapid antigen test turning positive again.) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Irritable bowel syndrome, GERD, Osteoporosis, Glaucoma, Allergy to antibiotic (doxycycline), Penicillin allergy and Drug allergy (oseltamivir). Concomitant products included FAMOTIDINE and SERTRALINE for an unknown indication.   On 12-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 09-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 19-Nov-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 07-May-2022, the patient experienced COVID-19 (Recurrence of COVID symptoms on 07-May-2022  after completing Paxlovid with negative rapid antigen test turning positive again.). The patient was treated with NIRMATRELVIR, RITONAVIR (PAXLOVID) (oral) from 27-Apr-2022 to 01-May-2022 for COVID-19 treatment, at an unspecified dose and frequency. At the time of the report, COVID-19 (Recurrence of COVID symptoms on 07-May-2022  after completing Paxlovid with negative rapid antigen test turning positive again.) was resolving.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 07-May-2022, SARS-CoV-2 test: positive (Positive) Positive. On an unknown date, SARS-CoV-2 test: negative (Negative) Negative.     For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   It was reported that the patient had taken other medications/products within 2 weeks of starting COVID-19 treatment.  Company comment: This spontaneous case concerns a patient (age, gender unspecified) with no relevant medical history, who experienced the unexpected non-serious of Covid-19, approximately 7 months after receiving the 3rd dose of mRNA-1273 vaccine. The patient took a course of Paxlovid (Nirmatrelvir + Ritonavir) for Covid-19 and later was tested negative. One week after the treatment the patient had rebound symptoms and tested positive for SARS-CoV-2 test. Details of medical history, clinical course, further investigation reports, and treatment were not provided. The outcome was reported as resolving. The patient had taken two primary doses of mRNA-1273 eight months prior to the third dose. The current pandemic situation of Covid-19 could be a confounder. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report. Sender's Comments: This spontaneous case concerns a patient (age, gender unspecified) with no relevant medical history, who experienced the unexpected non-serious of Covid-19, approximately 7 months after receiving the 3rd dose of mRNA-1273 vaccine. The patient took a course of Paxlovid (Nirmatrelvir + Ritonavir) for Covid-19 and later was tested negative. One week after the treatment the patient had rebound symptoms and tested positive for SARS-CoV-2 test. Details of medical history, clinical course, further investigation reports, and treatment were not provided. The outcome was reported as resolving. The patient had taken two primary doses of mRNA-1273 eight months prior to the third dose. The current pandemic situation of Covid-19 could be a confounder. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.